CURRICULUM VITAE (Rev. 8/20/2002)

Name: **MARVIN CHRIS MEYER**

Address: Marvin C. Meyer, Ph.D.
1700 SW 6th Ave.
Boca Raton, Florida 33486

Phone: 561-395-1409
FAX: 561-395-1473
EMAIL: MMEYER@UTMEM.EDU

Date of Birth: September 19, 1941

Place of Birth: Detroit, Michigan

Citizenship: U.S.A.

Marital Status: Married

Children: David John, born February 17, 1969, Memphis, Tennessee
Cheryl Lynn, born June 27, 1970, Memphis, Tennessee

Social Security Number: 374-44-1506

Educational Background:

Preparatory Training:	Denby High School, Detroit, Michigan Graduate 1959
Undergraduate Training:	Wayne State University, Detroit, Michigan B.S. in Pharmacy 1963
Graduate Training:	Wayne State University, Detroit, Michigan M.S. 1965 Major: Pharmaceutics
	State University of New York at Buffalo, Buffalo, New York Ph.D. 1969 Major: Pharmaceutics

Financial Support for Graduate Training:

Wayne State University: Undergraduate Teaching Assistant, 1963-1964

American Foundation for Pharmaceutical Education Fellowship, 1964-1965

S.U.N.Y. at Buffalo: American Foundation for Pharmaceutical Education Fellowship, 1965-1966

National Institutes of Health, Predoctoral Fellow, 1966-1968

Professional Experience:

Deaconess Hospital Detroit, Michigan	Intern/Pharmacist, 1960-1964
Department of Pharmaceutics College of Pharmacy University of Tennessee Center for the Health Sciences Memphis, Tennessee	Assistant Professor January 1969-December 1971
Division of Drug Metabolism and Biopharmaceutics Department of Medicinal Chemistry College of Pharmacy University of Tennessee Center for the Health Sciences Memphis, Tennessee	Director of the Division, Assistant Professor of Medicinal Chemistry and Pharmaceutics January-June 1972 Director of the Division, Associate Professor of Medicinal Chemistry and Biopharmaceutics July 1972-June 1976 Director of the Division, Professor of Medicinal Chemistry and Biopharmaceutics July 1976-June 1978
Division of Biopharmaceutics and Pharmacokinetics Department of Pharmaceutics College of Pharmacy University of Tennessee Center for the Health Sciences Memphis, Tennessee	Vice Chairman, Division Director and Professor of Pharmaceutics July 1978-June 1983 Director, Graduate and Research Programs - College of Pharmacy July 1980-June 1981 Assistant Dean for Graduate and Research Programs July 1981-June 1983 Associate Dean for Graduate and Research Programs February 1984- Acting Chairman, Dept. of Pharmaceutics July 1990-May 1991 Chairman, Department of Pharmaceutics May 1991 Acting Chairman, Dept. of Medicinal Chemistry October 1990-October 1991 Chairman, Department of Pharmaceutical Sciences Oct. 1991

Foreign Language: German

Memberships:

Honor Societies:

Rho Chi, National Pharmacy Honor Society

Omicron Delta Kappa - National Men's Honorary Leadership Society

McKenzie Honor Society - Wayne State University

Sigma Xi - National Research Honor Society

Phi Lambda Sigma - National Pharmacy Leadership Society

Professional and Scientific Organizations:

American Pharmaceutical Association

American Association of Colleges of Pharmacy

Phi Delta Chi - Professional Pharmaceutical Society

Memphis Area Society of Hospital Pharmacists

Tennessee Pharmaceutical Association

Memphis and Shelby County Pharmaceutical Society

Associate Fellow - American College of Apothecaries

Academy of Pharmaceutical Sciences

American Association of Pharmaceutical Scientists

Biographical Recognition:

Outstanding Educators of America

American Men and Women of Science

Personalities of the South

Who's Who in the South and Southwest

International Who's Who in Education

Who's Who in Frontier Science and Technology

Honors and Awards:

American Foundation for Pharmaceutical Education Fellow (1963-1966)

Public Health Service Fellow (1966-1968)

Donnley Award, Phi Delta Chi Award, Rexall Award, Medical Arts Award,
(Wayne State University)

Mead Johnson Undergraduate Research Award at the University of Tennessee (1970)

University of Tennessee National Alumni Association Public Service Award (1988)

Teacher of the Year, Pharmacy Class of 1992

Fellow, American Association of Pharmaceutical Scientists (1990)

Visiting Professor, College of Pharmacy, University of Clermont-Ferrand, France, May 1992

Appointed Member, FDA Advisory Committee for Pharmaceutical Sciences May 31, 2001-October 31, 2004.

Major University Appointments and Activities:

Advisor, Phi Delta Chi Fraternity

Elected Member, Academic Standing & Promotions Review Committee, UT College of Pharmacy (1974-1975)

Member, UT Advisory Committee for the Position of Dean of the College of Pharmacy (1975)

Chairman, Department of Pharmaceutics Graduate Admissions Committee (1978-present)

Chairman, College of Pharmacy Promotion and Tenure Committee

Member, UTCHS Graduate Program Review Committee (1978-1980)

Member, UTCHS Search Committee for Dean of the Graduate School (1980)

Member, President's Advisory Committee for Selection of a Chancellor (1980)

Member, UTCHS Research Committee (1980-present)

Member, UTCHS Graduate Council (1980-present)

Chairman, College of Pharmacy Graduate/Research Council (1980-present)

Member, UTCHS Graduate-Research Administration Council (1982)

Member, UTCHS Academic Affairs Council (1983)

Member, UT, Memphis Search Committee, Van Vleet Professor of Medicinal Chemistry (1986)

Member, UT, Memphis Search Committee, Graduate School Dean (1986-1987)

Member, College of Pharmacy Executive Advisory Committee (1983-Present)

Chairman, Search Committee for Graduate School Associate Dean for Research (1988)

Chairman, Search Committee for the Van Vleet Endowed Chair (1991-1992)

Ancillary Appointments and Activities:

Consultant for Palmer Chemical Company (1970-1971)

Scientific Review Panelist, American Pharmaceutical Association Drug Interactions Project (1972)

Consultant for Bioavailability Studies, Veterans Administration (1972)

Consultant for Krivscher and Cox Attorneys (1972-1974)

Consultant for Drug Abuse Testing Programs, National Collegiate Athletic Association (1973)

Ancillary Appointments and Activities (cont.d)

Expert for the United States Food and Drug Administration in Drug Bioavailability (1973-1976)

Participant in Workshop on Biochemical Approaches to Clinical Pharmacology, University of California San Francisco, Sponsored by National Academy of Sciences, Division of Medical Science (1973)

Consultant for Berlex Laboratories, Inc., Cedar Knolls, New Jersey (1975-1976)
Member, American Society of Hospital Pharmacists Review Panel, FDA Class Labeling Project (1976)

Consultant, Bell Pharmacal, Greenville, South Carolina (1976-1980)

Reviewer, NIH, National Institute of Child Health and Human Development (1978)

Visiting Professor, Roche Laboratories, Pharmaceutical Manufacturers Association Faculty Visitation Program (May 29-June 9, 1978)

Invited Lecturer for Food and Drug Administration Course in Biopharmaceutics and Pharmacokinetics, Rockville, Maryland (May 1-3, 1979; May 13-16, 1980; June 1-4, 1981)

Expert Witness for the U.S. Food and Drug Administration (Sept. 1980)

Consultant, Pfizer Pharmaceuticals, Inc. (1980-1981)

Consultant, Cord Laboratories, Inc. (1980-1987)

Consultant, Key Pharmaceuticals (1981-1988)

Consultant, Purdue Frederick (1982-1984)

Consultant, DuPont, Inc. (1982-1983)

Consultant, Pennwalt Corporation (1982-1983)

Consultant, PharmaKinetic Laboratories, Inc. (1982-1983)

Consultant, Forrest Laboratories, Inc. (1984)

Consultant, Ciba-Geigy (1984-1986)

Expert Witness, U.S. District Court, N.Y. (1984, 1985)

Consultant, International Drug Registration (1983-1987)

Consultant, Glaxo, Inc. (1983-1986)

Consultant, Sandoz Pharmaceuticals (1983-1986)

Consultant, Barr Laboratories (1984-1985, 1996-)

Biopharmaceutics Short Course Director, U.S. Food and Drug Administration, Rockville, Maryland, June 25-28, 1985

Ancillary Appointments and Activities (cont.d)

Member, Academy of Pharmaceutical Sciences, Dissolution Report Editorial Committee (1985)

Member, AACP Volwiler Award Committee (1986, 1987)

External Examiner, University of Tasmania (1985)

Consultant, Sidmak Laboratories (1987-present)

Member, Editorial Review Board, "Applied Pharmacokinetics," W.E. Evans, J. J. Schentag and William J. Jusko, Applied Therapeutics, Inc., Spokane, WA, 2nd Edition, 1986.

Member, Technical Advisory Board, Duramed Pharmaceuticals Cincinnati, OH (1986-1987)

Member, American Association of Pharmaceutical Scientists, Task Force on Bioequivalence, Washington, D.C. September 11, 1986

Consultant, Vitarine Pharmaceuticals, Inc. (1986-1992)

Consultant, Eon Laboratories (1992-)

Member, AACP Volwiler Research Achievement Award Committee (1986, 1987)

Member, Drug Standards Consultance Panel, The Upjohn Co. (1986-1990)

Member, External Board of Advisors, Pharmacokinetics Laboratory, Inc. (1987)

Member, Regulations and Science Policy Committee, American Association of Pharmaceutical Scientists (1988)

Consultant, FDA office of Orphan Products (1988, 1989, 1990)

Coordinator and Moderator, A.Ph.A. Scientific Symposium, Bethesda, Maryland, Sept. 16-17, 1988

Consultant, Schering Corp. (1988)

Consultant, Wyeth-Ayerst (1988)

Consultant, Reid-Rowell, Inc. (1989)

Consultant, Guidelines, Inc. (1989)

Expert Witness, Federal Court, Newark, N.J. (1989)

Consultant, UDL Laboratories (1990)

Consultant, Biocraft Laboratories (1990)

Consultant, Ciba-Geigy Canada (1990, 1991-1994)

Consultant, MOVA Pharmaceuticals (1990, 1992)

Ancilllary Appointments and Activities (cont.d):

Connsultant, NAPM (1990)

Consultant, Upjohn (1990, 1991)

Consultant, Searle Pharmaceuticals (1992)

Served as the course director for a course in biopharmaceutics & pharmacokinetics, presented to staff scientists in the FDA's Office of New Animal Drug Evaluation, Center for Veterinary Medicine, Rockville, Maryland, April 8-10, 1992

Consultant, Lemmon Pharmaceuticals (1992)

Consultant, Chelsea Laboratories (1994-)

Consultant, TimeRx Technologies (1994-)

Consultant, Copley Pharmaceuticals (1994-95)

Consultant, Zenith Laboratories (1994)

Selection Committee, AAPS New Investigator Grant (1996)

Expert - James V. Ball, Attorney, Memphis, TN (1997)

Consultant, Schein Laboratories (1999-2000)

Consultant, Pharmacia (1999-2000)

Consultant, Aventis (1999-2000)

Consultant, Blancett Pharmaceuticals (1999-2000)

Consultant, Advanced Care Products (1999-2000)

Consultant (2000-2001) for: Penwest (Scientific Advisory Board); Delsys (Scientific Advisory Board); Sidmak; Pharmacia; Andrx; Purepac; Endo; Banner Pharmacap; Blancett Pharmacal; Aventis; Barr Laboratories; Advanced Care Products; Schein/Watson

Consultant (2001-2002) for Penwest Scientific Advisory Board, Sidmak, Pharmacia, Barr Labs, Elite Laboratories, Morgan, Lewis & Bockius, Allied Clinical Research,

Expert: Snook, Hardy and Bacon - Pharmacia

Member, FDA's Pharmaceutical Sciences Advisory Committee (2001-2004)

Journal Reviewer:

Pharmaceutical Research

Journal of Pharmaceutical Sciences

American Journal of Pharmaceutical Education

Journal of Pharmacokinetics and Biopharmaceutics

Journal of Pharmaceutical Sci. (The Pharmaceutical Soc. Egypt)

Biopharmaceutics and Drug Disposition

International Journal of Pharmaceutics

Medical Letter

Archives of Internal Medicine

Chest

Clinical Pharmacy

Journal of the American Medical Association

Drug Intelligence and Clinical Pharmacy

Journal of Pharmacy Teaching

Courses Taught at the University of Tennessee:

Undergraduate: Pharmaceutical Technology

Biopharmaceutics

Graduate: Physico-Chemical Principles Pharmaceutical Systems

Kinetics of Pharmaceutical Systems

Advanced Pharmacokinetics

Supervision of Post-Doctoral Students:

A.F. Biola Mabadeje, M.D., Senior Lecturer in Pharmacology, College of Medicine, University of Lagos, Nigeria (1976-1977)

A.I. Attia, Ph.D., Associate Professor, Department of Pharmaceutics, Faculty of Pharmacy, University of Tanta, Egypt (1978)

Alade Akintonwa, Ph.D., Lecturer in Pharmacology, College of Medicine, University of Lagos, Nigeria (1982)

Sock Y. Tham, Ph.D., Lecturer, School of Pharmaceutical Sciences, University Sains Malaysia, Penang, Malaysia (1983)

N.K. Ebube, Ph.D., University of Mississippi (1995)

Joseph Chen, Ph.D., University of Memphis (1996)

Supervision of Graduate Students at the University of Tennessee:

Member, Graduate Committee for Khalid Nasim
M.S. in Pharmaceutics, 1970

Member, Graduate Committee for Javid Bashir
M.S. in Pharmaceutics, 1972

Member, Graduate Committee for Nutan Shah
Ph.D. in Pharmaceutics, 1974

Member, Graduate Committee for Bruce Boyette
Ph.D. in Medicinal Chemistry, 1974

Member, Graduate Committee for Vichai Wongchai
Ph.D. in Biochemistry, 1974

Major Professor for George Jones
M.S. in Pharmaceutics, 1974

Member, Graduate Committee for Paul Mui
Ph.D. in Biochemistry, 1975

Major Professor for Charles Cruze
Ph.D. in Medicinal Chemistry (Biopharmaceutics), 1977

Major Professor for Martin Yau
M.S. in Medicinal Chemistry (Biopharmaceutics), 1978

Member, Graduate Committee for Kay Puryear
M.S. in Pharmacology, 1978

Member, Graduate Committee for Bailey Lipscomb
Ph.D. in Medicinal Chemistry, 1978

Member, Graduate Committee for Michael Smith
M.S. in Pharmaceutics, 1978

Major Professor for Martin Yau
Ph.D. in Pharmaceutics, 1983

Member, Graduate Committee for Judith Bell
Ph.D. in Drug and Material Toxicology, 1983

Member, Graduate Committee for William Anderson
Ph.D. in Pathology, 1982

Member, Graduate Committee for David Vallari
Ph.D. in Biochemistry, 1986

Major Professor for Russell Rackley
Ph.D. in Pharmaceutics, 1989

Major Professor for Vijaykumar Vashi
M.S. in Pharmaceutics 1987

Major Professor for Vijaykumar Vashi
Ph.D. in Pharmaceutics 1991

Invited Presentations:

Southern School of Pharmacy, Mercer University, Atlanta, Georgia, January 16, 1971

Medicaid Title XIX Pharmacy Administrator's Seminar, Atlanta, Georgia,
November 16, 1972

College of Pharmacy, University of Nebraska, Lincoln, Nebraska, November 20, 1972

Annual Meeting, Memphis Area Society of Hospital Pharmacists, Memphis,
Tennessee, January 13, 1973

National Science Foundation Seminar, Christian Brothers College, Memphis, Tennessee, March 17, 1973

National Center for Toxicological Research, Pine Bluff, Arkansas, December 13, 1973

Memphis and Shelby County Pharmaceutical Society, Memphis, Tennessee, January 15, 1974
Invited Presentations:

American Association for the Advancement of Science, San Francisco, California,
February 27, 1974

Southern Association of Medicaid Administrators, Austin, Texas, March 26, 1974

Capitol City Representatives Seminar, Sponsored by Roche Laboratories, Atlanta, Georgia, June 17, 1974

World Health Information Service Symposium on "Revolution in Health Care",
Columbia, South Carolina, September 30, 1974

WKNO-TV Interview Program "Currents", Memphis, Tennessee, January 20, 1975

Tennessee Psychiatric Hospital and Research Institute, Memphis, Tennessee,
January 26, 1975

Eli Lilly Company, Indianapolis, Indiana, February 5, 1975

University of South Carolina, Continuing Education Program on Psychotherapeutic Drugs, Columbia,
South Carolina, February 26, 1975

Continuing Education Caribbean Cruise, Sponsored by ACA and Pharmasea,
March 8-15, 1975

Testimony before the Tennessee House Sub-Committee for Consumer Affairs, Nashville, Tennessee,
April 8, 1975

Association of Medicaid Pharmacy Administrators, Nashville, Tennessee,
September 24, 1975

District Ten Pharmaceutical Association, Columbia, Tennessee, October 23, 1975

District Six Pharmaceutical Association, Cookeville, Tennessee, January 28, 1976

WHBQ-TV (ABC) UTCHS Health Care Perspectives Television Program,
April 11, 1976

Middle Tennessee Society of Hospital Pharmacists, Nashville, Tennessee, April 15, 1976

Diamond Shamrock Corporation, Painsville, Ohio, November 2, 1976

Bell Pharmacal, Greenville, South Carolina, November 9, 1976

Visiting Professor of the Multinational Project on Chemistry of the OAS Regional Scientific and Technological Development Program, University of Panama, November 13-27, 1976

Bell Pharmacal, Greenville, South Carolina, November 6, 1976; January 12, March 28 and July 12, 1977

Symposium participant at the 37th International Congress of Pharmaceutical Sciences, The Hague, The Netherlands, September 6,1977

UTCHS College of Pharmacy Continuing Education Program, Nashville, Tennessee, January 22, 1978

University of Kentucky, Annual Kostenbauder Postgraduate Research Conference, October 20, 1978

Food and Drug Administration, Division of Biopharmaceutics, Research Seminar, Washington, D.C., February 15, 1979

Bell Pharmacal, Greenville, South Carolina, March 15, and April 26,1979

Association of Retired Military Officers, Millington, Tennessee, April 19, 1979

Super X Pharmacists? Regional Meeting, Fort Lauderdale, Florida, July 31, 1979

College of Pharmacy, University of Arkansas, Little Rock, Arkansas, November 1, 1979

Association of Medicaid Pharmacy Administrators, Chattanooga, Tennessee, October 23, 1979

19th Annual International Industrial Pharmacy Conference, Austin, Texas, February 28, 1980

Berlex Laboratories, Cedar Knolls, New Jersey, May 6, 1980

Veterans Administration Southeastern Regional Medical Education Center Program, Memphis, Tennessee, August 27, 1980

Middle Tennessee Society of Pharmacists, Nashville, Tennessee, October 23, 1990

Third Annual Pharmaceutical Development Conference, Medical University of South Carolina College of Pharmacy, Charleston, South Carolina, March 8-11, 1981

Roundtable Discussion of Graduate Education in the Pharmaceutical Sciences, A.Ph.A. Meeting, Las Vegas, NV, April 27, 1982

Pharmaceutical Technology Conference, New York, NY, September 22,1982

Roundtable Discussion on Theophylline, American Academy of Allergy and Immunology, Hollywood, Florida, March 20, 1983

UTCHS, TSHP and Dista Products Company Continuing Education Program, "Scientific and Clinical Principles of Pharmacokinetics", Memphis, Tennessee, September 9, 1983

Tennessee Society of Physicians Assistants Annual Conference, Nashville, Tennessee, September 16, 1983

UTCHS and Sandoz Pharmaceuticals Continuing Education Program, "Choice of Antipsychotic Drugs", Tri-Cities (October 9, 1983), Chattanooga (October 30, 1983) and Jackson, Tennessee (November 20, 1983)

Academy of Pharmaceutical Sciences Symposium, "Critique of the USP Policy on Modified Release Dosage Forms", Miami, Florida, November 15, 1983

New York Academy of Sciences Symposium, "A New Approach to theManagement of Opioid Dependence: Naltrexone, and Oral Antagonist", New York, New York, November 7, 1983

State University of New York, College of Pharmacy Symposium Honoring Dean Daniel Murray, Buffalo, New York, April 28, 1984

Upjohn Company, Kalamazoo, Michigan, May 10, 1984

26th Annual National Industrial Pharmaceutical Research Conference, University of Wisconsin, Lake Delton, Wisconsin, June 12, 1984

Pharmaceutical Society, Sheffield, Alabama, February 10, 1985

Black Pharmacists Society, Memphis, Tennessee, May 19, 1985

Ciba-Geigy, Pharmaceuticals Division, Summit, New Jersey, May 30, 1985

Kentucky Third District Pharmaceutical Society, Bowling Green, Kentucky, September 12, 1985

Rutherford County Pharmaceutical Society, Murfreesboro, Tennessee, September 13, 1985

Chattanooga-Hamilton County Pharmaceutical Society, Chattanooga, Tennessee, September 15, 1985

Drug Information Association, Workshop on Controlled Release Dosage Forms, Washington, D.C., September 30, 1985

Sackler School of Graduate Biomedical Sciences, Tufts University, Boston, Massachusetts, December 4-5, 1985

Memphis and Shelby County Pharmaceutical Society, Memphis, Tennessee, January 14, 1986

Hahneman University Conference on Bioequivalence, Philadelphia, Pennsylvania, February 10, 1986

Northwest Mississippi Regional Medical Center, Clarksdale, Mississippi, February 18, 1986

International Industrial Pharmacy Conference, University of Texas at Austin, Montgomery, Texas, February 23-27, 1986

Dickson Area Pharmaceutical and Medical Societies, Dickson, Tennessee, April 3, 1986

Tennessee Pharmaceutical Association, Nashville, TN, June 9, 1986

Tufts University "Postmarketing Surveillance Program", Boston, MA, July 9-10, 1986

American College of Apothecaries Annual Meeting, Toronto, Canada, August 17, 1986

Pfizer Pharmaceuticals, New York, NY, September 2, 1986

Hahnemman University, Bioequivalence Program, Washington, D.C., September 29, 1986

Family Medical Center Healthplex Baptist Hospital, Memphis, TN, October 2, 1986

Gulf Coast Pharmaceutical Assoc., Fort Myers, Florida, October 8, 1986

First District Pharmaceutical Association, Johnson City, TN, November 23, 1986

Vanderbilt Hospital, Nashville, Tennessee, January 15, 1987

Oral Controlled Release Dosage Forms Symposium, Nortec Development Associates, Woodcliff Lake, N.J. March 11, 1987

UT Alumni Weekend Symposium, Memphis, TN. Sept. 18, 1987

Rocky Mountain Drug Consultation Center Symposium, Denver, Co., Nov. 9, 1987

Memphis and Shelby County Pharmaceutical Society, Memphis, TN, Sept. 14, 1988

Moderator - APhA Scientific Symposium on Bioequivalence, Bethesda, Maryland, Sept. 16-17, 1988

Memphis & Shelby Co. Pharmaceutical Soc., "Dosage Forms of the Future", Memphis, Tennessee, Sept. 14, 1988

St. Mary's Medical Center, "Novel Drug Delivery Systems", Knoxville, Tennessee, Oct. 25, 1988

Methodist Medical Center, "Novel Drug Delivery Systems", Knoxville, Tennessee, Oct. 25, 1988

Glaxo Symposium, "Clinical Pharmacokinetics of Albuterol Controlled-Release Dosage Forms", Laguna Niguel, California, April 28, 1989

Greater Knoxville Epilepsy Foundation Annual Meeting, Knoxville, TN, September 9, 1989

SynerMed Roundtable Discussion of Generic Drug Products, Los Angeles, CA, September 18, 1989

Bio International '89 Symposium, Toronto, Canada, October 1-4, 1989

American Association of Pharmaceutical Scientists, Panel Moderator, Atlanta, GA, October 22-26, 1989

FDA Advisory Committee Meeting on Conjugated Estrogens, Rockville, MD., May 3, 1990

AAPS Regional Meeting, Chicago, Ill., May 14, 1990

Biocraft Laboratories sponsored round-table discussion of generic drugs, Fair Lawn, NJ, September 17, 1990

Wisconsin Pharmacists Association Annual Meeting, Oconomowoc, WI., September 22, 1990

Conference on Bioequivalence, McGill University, Montreal Canada, March 28-31, 1991

University of Montreal Symposium, Montreal Canada, April 21-24, 1991

American Society for Hospital Pharmacists Annual Meeting, Symposium on Antiepileptic Drugs and Pharmacy Practice, New Orleans, December 10, 1991

American Pharmaceutical Association Annual Meeting, San Diego, CA, Symposium on Variable Affecting Drug Product Efficacy, March 14, 1992

University of Clermont-Ferrand Annual Industry-Academic Symposium, Clermont-Ferrand France, May 13-15, 1992

SynerMed Roundtable Discussion on Generic Drugs, Arlington, VA, July 25, 1992

Ciba-Geigy Pharmaceuticals, Ardsley, NY, July 27, 1992

SynerMed Roundtable Discussion on Anticonvulsant Drug Therapy, New York, October 27, 1992

Upjohn Company, Kalamazoo, Michigan, May 17, 1994

M. Meyer. "Current Scientific Issues Regarding BA/BE Studies: An Academic View." DIA Workshop, Rockville, MD, Sept. 1994

M. Meyer, "FDA Sponsored Research at the University of Tennessee", Food and Drug Administration, Rockville, MD, Nov. 17, 1994

M. Meyer, "Overview of Research in the Pharmaceutical Sciences", Hoechst Research Day, University of Tennessee, Knoxville, TN, Feb. 1995

M. Meyer. "Highly Variable Drugs", AAPS/FDA Workshop, Crystal City VA, March 1995

Meyer, M.C., Use of Special Populations in Phase I Trials, AAPS Open Session on Special Populations, Seattle, WA, October 29, 1996

Meyer, M.C., In Vitro-In Vivo Examples, AAPS/FDA/CRS Workshop "Scientific Foundations for Regulating Drug Product Quality", Crystal City, VA, April 15, 1997

Meyer, M.C. Bioequivalence Issues: Past, Present and Future, College of Pharmacy, University of Arkansas, Little Rock, AR, April 25, 1997

Meyer, M.C. FDA Sponsored Bioequivalence Studies at the University of Tennesee, Food and Drug Administration, Rockville, MD, August 18, 1997

Hard and Soft Gelatin Capsules: Issues, Research and Outcome: Bioequivalence Studies, AAPS Invited Podium Session, Boston, MA, Nov. 5, 1997

FDA Advisory Committee Meeting on Narrow Therapeutic Index Drugs, Rockville, MD., December 11, 1997

Minnesota Drug Formulary Commission, Minneapolis, MN August 7, 1998.

Illinois Legislative Conference Committee, Indianapolis, IN, Sept. 2, 1998

Grand Rounds, Abbington PA Memorial Hospital, May 18, 1999

Ohio Senate Committee on Health Care, Columbus OH, May 19, 1999

"Perspectives and Points of View - Pharmaceutical Sciences", AAPS International Workshop on Individual Bioequivalence, Montreal, Canada, September 1999

Presentation to the Florida Senate Committee on Generic Drug Formularies, Nov. 3, 1999

"Why Failed Bioequivalence Studies - Science and Technical Issues", Symposium at AAPS Meeting, New Orleans, LA, Nov. 14, 1999

Invited Presentations (cont.d):

"Research Programs at the University of Tennessee College of Pharmacy", at the National Center for Toxicology Research, Jefferson, Arkansas, April 4, 2000

FDA/AAPS Workshop - Biopharmaceutics in the New Millennium, Washington, DC September 13, 2000

Thesis and Dissertation:

M.S. - "The Interaction of Atropine with Kaolin"
Ph.D. - "The Binding of Drugs by Plasma Proteins"

Textbook:

1. "Complexation", Chapter 12, p. 558-591. In E.W. Martin, Ed., Dispensing of Medication, 7th Ed., Mack Publishing Co., Easton, Pa., 1971.

2. "Medication Orders," Chapter 1. In E.W. Martin, Ed., Dispensing of Medication, 8th Ed., Mack Publishing Co., Easton, Pa., 1987.

3. "Complexation", Chapter 14, Remington's Pharmaceutical Sciences-17th Edition, Mack Publishing Co., Easton, Pa., 1985.

4. "Bioavailability of Drugs" and "Bioequivalence", Encyclopedia of Pharmaceutical Technology, J. Swarbrick and J. Boylan, eds. Marcel Dekker, Inc., Vol. 1, P. 477-493(1988).

5. "Bioavailability of Transdermal and Topical Dosage Forms", in Bioavailability and Bioequivalence, ed. P. Welling, F. Tse and S. Dighe, Marcel Dekker, N.Y., P. 169-223 (1991).

6. "IVIVC Examples", in Scientific Foundations for Regulating Drug Product Quality, ed. G. Amidon, J. Robinson and R. Williams, AAPS Press Alexandria, VA, P. 329-345, October 1997.

7. Dalton, JT and Meyer MC. "Bioavailability of Drugs" and "Bioequivalence", Encyclopedia of Pharmaceutical Technology, J. Swarbrick and J. Boylan, eds. Marcel Dekker, Inc., (In press, 2000)

Publications:

1. "Interactions of Xanthine Derivatives with Bovine Serum Albumin III - Inhibition of Binding". M.C. Meyer and D.E. Guttman, J. Pharm. Sci., 57, 245 (1968).

2. "The Binding of Drugs by Plasma Proteins". M.C. Meyer and D.E. Guttman, J. Pharm. Sci., 57, 895 (1968).

3. "A Novel Method for Studying Protein Binding". M.C. Meyer and D.E. Guttman, J. Pharm. Sci., 57, 1627 (1968).

4. "The Pharmacist and Generic Equivalence". M.C. Meyer, Tennessee Pharmacist, 5, 6 (1969)

5. "Dynamic Dialysis as a Method for Studying Protein Binding I. - Factors Affecting the Kinetics of Dialysis through a Cellophane Membrane". M.C. Meyer and D.E. Guttman, J. Pharm. Sci., 59, 33 (1970).

6. "Dynamic Dialysis as a Method for Studying Protein Binding II. - Evaluation of the Method with a number of Binding Systems." M.C. Meyer and D.E. Guttman, J. Pharm. Sci., 59, 39 (1970).

7. "Theoretical Drug Levels During Multiple Dosing in a Two-Compartment Open Model". M.C. Meyer, Arch. Int. Pharmacodyn. 193, 141 (1971).

8. "Permeation of Solutes Through Polyethylene I. The Effects of Structure on Permeability of a Series of Aniline Derivatives". D.G. Serota, M.C. Meyer and J. Autian, J. Pharm. Sci., 61, 416 (1972).

9. "Permeation of Aromatic Organic Compounds from Aqueous Solutions Through Polyethylene". K. Nasim, M.C. Meyer and J. Autian, J. Pharm. Sc., 61, 1775 (1972).

10. "Bioavailability of Fourteen Nitrofurantoin Products". M.C. Meyer, G.W.A. Slywka, R.E. Dann and P.L. Whyatt, J. Pharm. Sci., 63, 1693 (1974).

11. "The Bioavailability of Sixteen Tetracycline Products". M.C. Meyer, R.E. Dann, P.L. Whyatt, and G.W.A. Slywka, J. Pharmacokin. Biopharm. 2, 287 (1974).

12. "The Role of State Formularies in Providing Quality Drug Products Economically". M.C. Meyer, H. Bates, R.G. Swift, J.A.Ph.A., NS 14, 663 (1974).

13. "Rapid, Precise Turbidimetric Assay for Low Levels of Ampicillin in Serum After Single Dose Oral Administration". P.L. Whyatt, R.E. Dann, G.W.A. Slywka and M.C. Meyer, Antimicrobial Agents and Chemotherapy, 6, 811 (1974).

14. "The Tennessee Drug Quality Assurance program". P.L. Whyatt, G.W.A. Slywka, A.P. Melikian, H.E. Bates and M.C. Meyer, Tennessee Pharmacist, 11, 12 (1975).

15. "Inequivalency of Nitrofurantoin Products". M.C. Meyer, G.W.A. Slywka, P.L. Whyatt and A.P. Melikian, J.A.M.A., 232, 1009 (1975).

16. "Propoxyphene Bioavailability: An Evaluation of Ten Products". G.W.A. Slywka, A.P. Melikian, P.L. Whyatt and M.C. Meyer, J. Clin. Pharmacol., 15, 598 (1975).

17. "The Binding of Salicylate and Sulfathiazole by Whole Blood Constituents". C. Cruze and M.C. Meyer, J. Pharm. Sci., 65, 33 (1976).

18. "Hydrochlorothiazide Bioavailability: An Evaluation of Thirteen Products". M.C. Meyer, A.P. Melikian, P.L. Whyatt and G.W.A. Slywka, Curr. Ther. Res., 17, 570 (1975).

19. "Folic Acid Administration to Chronic Hemodialysis Patients". V.A. Skoutakis, S.R. Acchiardo, M.C. Meyer and F.E. Hatch, Clin. Pharmacol. Ther., 18, 200 (1975).

20. "The Bioavailability of Seventeen Ampicillin Products". P.L. Whyatt, G.W.A.

Slywka, A.P. Melikian and M.C. Meyer, J. Pharm. Sci., 65, 652 (1976).

21. "Hydrochlorothiazide Bioavailability Monograph". M.C. Meyer and P.L. Whyatt, J.A.Ph.A., NS 16, 47 (1976).

22. "Bioavailability of 11 Sulfisoxazole Products in Humans". G.W.A. Slywka, A.P. Melikian, A.B. Straughn, P.L. Whyatt and M.C. Meyer, J. Pharm. Sci., 65, 1494 (1976).

23. "The Relationship of Price to Bioavailability for Four Multiple Source Drug Products". G.W.A. Slywka, M.R. Ryan, A.P. Melikian, M.C. Meyer, H.E. Bates and P.L. Whyatt, J.A. Ph.A., NS 17, 30 (1977).

24. "Bioavailability of Eleven Phenytoin Products". A.P. Melikian, A.B. Straughn, G.W.A. Slywka, P.L. Whyatt and M.C. Meyer, J. Pharmacokin. Biopharm., 5, 133 (1977).

25. "Drug Interactions Involving Aminosalicylic Acid". M.C. Meyer, T.H. Self and A.B. Straughn, Reviews on Drug Interactions, 2, 107 (1977).

26. "Estimations of Drug Dosing Regimens with A Pharmacokinetic Slide Rule". A.B. Straughn, C.A. Cruze and M.C. Meyer, Am. J. Hosp. Pharm., 34, 197 (1977).

27. "Meprobamate Bioavailability Monograph". M.C. Meyer and A.B. Straughn, J.A.Ph.A., 17. 173 (1977).

28. "The Role of Drug Equivalency and Bioavailability in Formulary Determination". M.C. Meyer, Revolution in Health Care, 1, 33 (1975).

29. "Factors Affecting the Bioavailability of Chlorothiazide in Man". M.C. Meyer and A.B. Straughn, Curr. Ther. Res., 22, 573-582 (1977).

30. "The Relative Bioavailability of Meprobamate Tablets in Man". M.C. Meyer, A.P. Melikian and A.B. Straughn, J. Pharm. Sci., 67, 1290-1292 (1978).

31. "The Bioavailability of Sulfadiazine Solutions, Suspensions and Tablets in Man". M.C. Meyer, A.B. Straughn, G. Ramachander, J.C. Cavagnol and A.F.B. Mabadeje, J. Pharm. Sci., 67, 1659-1661 (1978).

32. "The Influence of Dosage Form on Papaverine Bioavailability". M.C. Meyer, R. Gollamudi and A.B. Straughn, J. Clin. Pharmacol, 19, 435 (1979).

33. "Simultaneous Determination of Methenamine and Formaldehyde in the Urine of Humans After Methenamine Administration.". R. Gollamudi, M.C. Meyer and A.B. Straughn, Biopharm. Drug Disposition, 1, 27 (1979).

34. "The Bioavailability of Chlorothiazide Tablets in Man". A.B. Straughn, A.P. Melikian and M.C. Meyer, J. Pharm. Sci., 68, 1099 (1979).

35. "A HPLC Assay for the Determination of Griseofulvin in Plasma". M.C. Meyer and G. Raghow, J. Pharm. Sci., 68, 1127 (1979).

36. "A Multiple-Dose Study of Sustained-Release Theophylline and Aminophylline". M.C. Meyer, A.B. Straughn and P. Lieberman, Chest, 78, 300 (1980).

37. "The Bioavailability of Microsize and Ultramicrosize Griseofulvin Product in Man". A.B. Straughn, M.C. Meyer, G. Raghow and K. Rotenberg, J. Pharmacokin. Biopharm., 8 347 (1980).

38. "Evaluation of Enzyme Immunoassay, Radioassay, and Radioimmunoassay of Serum Methotrexate, with Liquid Chromatography as a Standard". R.G. Buice, W.E. Evans, J. Karas, C.A. Nicholas III, P. Sidhu, A.B. Straughn, M.C. Meyer and W.R. Crom, Clin. Chem., 26, 1902 (1980).

39. "Pharmacokinetics of Propylthiouracil Upon P. O. Administration in Man". H.P. Ringhand, W.A. Ritschel, M.C. Meyer, A.B. Straughn and T. Hardt, Intl. J. Clin. Pharmacol. Ther. Toxicol., 18, 3011 (1980).

40. "Urinary Excretion of Methenamine and Formaldehyde: An Evaluation of Ten Methenamine Products in Man". R. Gollamudi, A.B. Straughn and M.C. Meyer, J. Pharm. Sci., 70, 596 (1981).

41. "The Determination of Trichlormethiazide in Human Plasma and Urine by HPLC". M.C. Meyer and P.T.R. Hwang, J. Chromatogr., 223, 466-472 (1981).

42. "HPLC Assay of Tolbutamide and Carboxytolbutamide in Human Plasma". G. Raghow and M.C. Meyer, J. Pharm. Sci., 70 1166-1168 (1981).

43. "In Vivo-In Vitro Correlations with the Sartorius Dissolution Simulator I: Methenamine, Nitrofurantoin and Chlorothiazide". M.K.T. Yau and M.C . Meyer, J. Pharm. Sci., 70, 1017-1024 (1981).

44. "Pharmacokinetics of Trichlormethiazide in Hypertensive Patients with Normal or Comprised Renal Function." I.S. Sketris, V.A. Skoutakis, S.R. Acchiardo and M.C. Meyer, Europ. J. Clin. Pharmacol., 20, 453 (1981).

45. "HPLC Determination of Benzthiazide in Biologic Material." M.C. Meyer, P. Hwang, A.B. Straughn and K. Rotenberg, Biopharm. Drug Disposit., 3, 109 (1982).

46. "Serious Bioavailability Problems with a Generic Prolonged-Release Quinidine Gluconate Product." M.C. Meyer, A.B. Straughn, P. Lieberman and J. Jacob, J. Clin. Pharmacol. , 22, 131-134 (1982).

47. "Relative Bioavailability of Acetazolamide Tablets." A.B. Straughn, R. Gollamudi and M.C. Meyer, Biopharm. Drug Disposit. 3, 75-82 (1982).

48. "Hexoprenaline Pharmacokinetics in Pregnant and Nonpregnant Sheep." J. Lipshitz, M.K.T. Yau, M.C. Meyer, R.A. Aokas, A.L. Maduska, W.D. Whybrew, G.D. Anderson, J.C. Morrison and J. Schneider, Res. Commun. Chem. Pathol. Pharmacol., 34, 3-16 (1981).

49. "Bioavailability of Propylthiouracil in Humans." H.P. Ringhand, W.A. Ritschel, M.C. Meyer, A.B. Straughn and B.E. Cabana, J. Pharm. Sci., 72, 1409-1412 (1983).

50. "In Vivo-In Vitro Correlations with the Sartorius Dissolution Simulator II: Papaverine, Phenytoin and Sulfisoxazole." M.K.T. Yau and M.C. Meyer, J. Pharm. Sci., 72, 681-686 (1983).

51. "High-Performance Liquid Chromatographic Micro-Assay for Cefoperazone in Human Plasma, Urine and CSF." P.T.R. Hwang and M.C. Meyer, J. Liq. Chromatogr. 6, 743-754 (1983).

52. "Chloramphenicol Dosage and Pharmacokinetics in Infants and Children." G.J. Burckart, F.F. Barrett, R. Della Valle and M.C. Meyer, J. Clin. Pharmacol. 23, 210-216 (1983).

53. "Nonlinear Ethotoin Kinetics." M.C. Meyer, B.J. Holcombe, G.J. Burckart, G. Raghow and M.K. Yau, Clin. Pharmacol. Ther., 33, 329-334 (1983).

54. "Phenytoin, Part I: In Vitro/In Vivo Correlation for 100 mg Sodium Phenytoin Capsules." V.P. Shah, V.K. Prasad, T. Alston, B.E. Cabana, R.P. Gural and M.C. Meyer, J. Pharm. Sci., 72, 306-308 (1983).

55. "Importance of Media Selection in Establishment of In Vitro-In Vivo Relationships for Quinidine Gluconate." V.K. Prasad, V.P. Shah, P. Knight, H. Malinowski, B.E. Cabana and M.C. Meyer, Int. J. Pharmaceut., 13, 1-7 (1983).

56. "Absorption of Phenobarbital from Tablets and Elixir." M.C. Meyer, A.B. Straughn, G. Raghow, W.L. Schary and K.S. Rotenberg, J. Pharm. Sci., 73, 485-488 (1984).

57. "Plasma Levels of Ethaverine After Oral Administration to Humans." M.C. Meyer, G. Raghow and A.B. Straughn, Biopharm. Drug Disposit., 4, 401-404 (1983).

58. "Placental Transfer of Chloroquine in Pregnant Rabbits." A. Akintonwa and M.C. Meyer, Res. Commun. Chem. Path. Pharmacol., 40, 45(1983).

59. "Simultaneous Determination of Chloroquine and Desethylchloroquine in Blood, Plasma and Urine by High-Performance Liquid Chromatography." J. Liq. Chromatogr., 6, 1513-1522 (1983).:

60. "Bioequivalence, Dose-proportionality and Pharmacokinetics of Naltrexone After Oral Administration." M.C. Meyer, A.B. Straughn, M.L. Lo, W.L. Schary and C.C. Whitney, J. Clin. Psych., 45, 9-15 (1984)

61. "HPLC Determination of Ceftazidime in Serum, Urine, CSF and Peritoneal Dialysis Fluid." P.T.R. Hwang, P.G. Drexler and M.C. Meyer, J. Liq. Chromatogr., 7, 979-987 (1984).

62. "Bioavailability and Bioequivalence," M.C. Meyer, Ther. Drug Monitor Toxicol., 6, 1-7 (1984).

63. "A Chronopharmacokinetic Model for Sustained-Release Formulations," A.B. Straughn, M.C. Meyer, A. Golub and M.A. Gonzalez, Ann. Rev. Chronopharmacology, 1, 93-96 (1985).

64. "Administration of Theo-Dur Once Daily vs. Twice Daily," A.B. Straughn, M.C. Meyer, A.L. Golub, M.A. Gonzalez, In: Sustained Release Theophylline and Nocturnal Asthma, International Workshop, Burgenstock, Switzerland, Ed. A.F. Isles and P. von Wichert, Excerpta Medica, 1985, pp. 116-124.

65. "Bioavailability of Dyphylline and Dyphylline-guiafenesin Tablets in Humans," A.B. Straughn, G.C. Wood, G. Raghow and M.C. Meyer, J. Pharm. Sci., 74, 335-337 (1985).

66. "High-Performance Liquid Chromatographic Determination of Acetazolamide in Human Plasma," P.T.R. Hwang, J.R. Lang, G.C. Wood and M.C. Meyer, J. Liq. Chromatogr. , 8, 1465-1473 (1985).

67. "Bioavailability of Seven Furosemide Tablets in Man," A.B. Straughn, G.C. Wood, G. Raghow and M.C. Meyer, Biopharm. Drug Disposit., 7, 113-120 (1986).

68. "Determination of Free Disopyramide Plasma Concentrations Using Ultrafiltration and EMIT," G. Raghow, M.C. Meyer and A.B. Straughn, Ther. Drug Monit., 7, 466-471 (1985).

69. "Nalmefene: Intravenous Safety and Kinetics of a New Opioid Antagonist," R. Dixon, J. Howes, J. Gentile, H. Hsu, J. Hsiao, D. Garg, D. Weidler, M.C. Meyer and R. Tuttle, Clin. Pharmacol. Ther., 39, 49-53 (1986).

70. "Dialyzability and Pharmacokinetics of Indomethacin in Adult Patients with End-

Stage Renal Disease," V. A. Skoutakis, C. Carter, N.J. Wojciechowski, A.B. Straughn and M.C. Meyer. Drug Intelligence and Clin. Pharm., 20, 956 (1986).

71. Monograph - "The Therapeutic Equivalence of Drug Products - A Second Look," M.C. Meyer, 99 pages, Public Planning Department, Hoffman-LaRoche, Inc., Nutley, NJ , 1985.

72. "Proceedings of the Food and Drug Administration Bioequivalence Hearing," September 29th-October 1, 1986, pages 89-116, 293-312 and 579-592.

73. "Influence of a Standard Meal on the Absorption of a Controlled-Release Pseudoephedrine Suspension," D.A. Graves, M.T. Wecker, M.C. Meyer, A.B. Straughn, L.P. Amsel, O.N. Hinsvark, A.E. Bhargava and K.S. Rotenberg, Biopharm. and Drug Disposit., 9, 267-272 (1988).

74. "Bioavailability of a Controlled-Release Albuterol Formulations for Twice-Daily Use," R.S. Sykes, M.E. Reese and M.C. Meyer, Biopharm. and Drug Disposit., 9, 551-556 (1988).

75. "Effect of Dose and Food on the Bioavailability of Cefuroxime Axetil," A. Finn, A. Straughn, M. Meyer and J. Chubb, Biopharm. and Drug Disposit., Vol. 8, 519-526 (1987).

76. "The Absorption of Sustained-Release Methylphenidate Formulations Compared to an Immediate-Release Formulation," K.S. Patrick, A.B. Straughn, E.J. Jarvi, G.R. Breese and M.C. Meyer, Biopharm. and Drug Dispos. 10, 165-172 (1989).

77. "A Circadian Rhythm in Theophylline Disposition During a Constant-Rate Intravenous Infusion of Aminophylline in the Dog," R. J. Rackley, A.B. Straughn, and M.C. Meyer, J. Pharm. Sci., 77, 658-661 (1988).

78. "Chronopharmacokinetic Simulation of a Circadian Rhythm in Theophylline Disposition During a Constant-Rate Intravenous Infusion of Aminophylline in the Dog," R. J. Rackley, A.B. Straughn, and M.C. Meyer, Ann. Review of Chronopharmacology, Vol. 5, 205-208 (1988).

79. "The Effect of pH on the In Vitro Dissolution and the In Vivo Absorption of Controlled-Release Theophylline in Dogs," V.I. Vashi and M.C. Meyer, J. Pharm. Sci. 77, 760-764 (1988).

80. "Gas Chromatographic-Mass Spectrometric Analysis of Plasma Oxybutynin Using a Deuterated Internal Standard," K.S. Patrick, J.S. Markowitz, E.J. Jarvi, A.B. Straughn and M.C. Meyer, J. Chromat. BioMed. Applic., 487, 91-98 (1988).

81. "In Vitro and In Vivo Evaluation of Seven 50mg and 100mg Nitrofurantoin Tablets," M.C. Meyer, G.C. Wood and A.B. Straughn, Biopharm. Drug Disposition, Vol. 10, 321-329 (1989).

82. "Gas Chromatographic-Mass Spectrometric Analysis of Plasma Nifedipine", K.S. Patrick, E.J. Jarvi, A.B. Straughn and M.C. Meyer, J. Chrom. (Biomed. App.) 495:123 (1989).

83. "Circadian Rhythms in Theophylline Disposition: Simulations and Observations in the Dog," R.J. Rackley, M.C. Meyer and A.B. Straughn, J. Pharm. Sci. 80:824-829 (1991).

84. "Generic Drug Products - The Tennessee Approach," M.C. Meyer, Tenn. Pharm., 26, 12-13 (1990).

85. "Scientific Basis of Bioavailability and Bioequivalence Testing," M.C. Meyer, Am. Pharm. 31:47-53 (1991).

86. "The Effect of Raising Gastric pH with Ranitidine on the Absorption and Elimination of Theophylline from a Sustained-Release Theophylline Tablet," C.J. Betlach, A.B.

Straughn, M.C. Meyer, M. Bialer, V.I. Vashi, P. Lieberman and M.A. Gonzalez, Pharm. Res., 81:1516-1519 (1991).

87. "The Bioinequivalence of Carbamazepine Tablets with a History of Clinical Failures," M.C. Meyer, A.B. Straughn, E.J. Jarvi, G.C. Wood, F.R. Pelsor and V.P. Shah, Pharm. Res. 9, 1612-1616 (1992).

88. "Quantitative Determination of Cyclobenzaprine in Human Plasma by High Pressure Liquid Chromatography," P.T.R. Hwang, D.A. Young, A.B. Straughn and M.C. Meyer, J. Liq. Chromatography, 16,1163-1171 (1993).

89. "The Effect of Gastric pH on the Absorption of Controlled-Release Theophylline Dosage Forms in Humans," M.C. Meyer, A.B. Straughn, E.J. Jarvi, G.C. Wood, V.I. Vashi, P. Hepp and J. Hunt, Pharm. Res. 10, 1037-1045 (1993).

90. "Biopharmaceutical Factors in Seizure Control and Drug Toxicity," M.C. Meyer and A.B. Straughn, Am. J. Hosp. Pharm. 50, Suppl. 5, S17-S22 (1993) .

91. "Current Scientific Issues Regarding Bioavailabilty/Bioequivalence Studies: An Academic View," M.C. Meyer, Drug Information Journal, v. 29 (1995), Drug Information J. 29, 805-812 (1995).

92. "Relating Formulation Variables to In Vitro Dissolution Using an Artificial Neural Network," N.K. Ebube, T. McCall, Y. Chen and M.C. Meyer, Pharmaceutical Development and Technology, 2:225-232 (1997).

93. "IVIVC Examples", Meyer, M.C. in Scientific Foundations for Regulating Drug Product Quality, p. 353-371 (1997), AAPS Publ.

94. Meyer, MC, Straughn, AB, Mhatre, R, Shah, V, Williams, RL and Lesko, L. The Relative Bioavailability and In Vivo-In Vitro Correlations for Four Marketed Carbamazepine Tablets, Pharm. Res. 15:1787-1791 (1998).

95. Meyer, MC, Bolton, S and Chan, K. Generic Warfarin: Implications for Patient Care - Another View. Pharmacotherapy, 18:884-886 (1998)

96. Meyer, MC. Generic Drug Product Equivalence: Current Status. Am. J. Managed Care. 43:100-109 (1998).

97. Meyer, MC, Straughn, AB, Mhatre, RM, Shah, VP, Williams, RL and Lesko, LJ. Lack of In Vivo/In Vitro Correlations for 50mg and 250mg Primidone Tablets, Pharm. Res. 15:1085-1089 (1998).

98. Chen, Y, McCall, T, Baichwal, AR and Meyer, MC. The Application of an Artificial Neural Network and pharmacokinetic Simulations in the Design of Controlled-Release Dosage Forms. J. of Controlled Release, 59:33-41(1999).

99. Dalton, JD, Meyer, MC and Golub, AL. Pharmacokinetics of Aminolevulinic Acid after Oral and Intravenous Administration in Dogs. Drug Metabolism and Disposition. 27:432-435 (1999).

100. Beyssac E, Touaref F, Meyer MC, Jacob L, Sandopuk P and Aiache JM. Bioavailability of Morphine after administration of a new bioadhesive buccal tablet, Biopharm Drug Dispos. 19:401-405 (1998).

101. Dalton, JT, Zhou, D, Mukherjee, A, Young, D, Tolley, EA, Golub, AL and Meyer, MC. Pharmacokinetics of Aminolevulinic Acid and Intravesical Administration to Dogs. Pharm. Res., 16:288-295 (1999)

102. Kidd RS, Straughn AB, Meyer MC, Goldstein JA and Dalton JD. Pharmacokinetics of Chlorpheniramine, Phenytoin, Glipizide and Nifedipine in an Individual Homozygous for the CYP2C9*3 Allele. Pharmacogenetics, 9:71-80 (1999).

103. Meibohm, B, Zhang, Z, Beierle, I, Meyer, M. Epistaxis Associated with Elevation of INR in a Patient Switched to Generic Warfarin - Another View. Pharmacotherapy 20:866-869 (2000)

104. Meyer, MC, Jarvi, EJ, Straughn, AB, Pelsor, FR, Williams, RL and Shah, VP, Bioequivalence of Immediate-release Theophylline Capsules, Biopharm. Drug Dispos. 20, 417-419 (1999)

105. Meyer, MC, Straughn, AB, Jarvi, EJ, Patrick, KS, Pelsor, FR, Williams, RL, Patnaik, R, Chen, ML and Shah, VP, Bioequivalence of Methylphenidate Immediate-Release Tablets Using a Replicated Study Design to Characterize Intrasubject Variability, Pharm. Res. 17, 381-384 (2000)

106. Meyer, MC. "United States Food and Drug Administration Requirements for Approval of Generic Drug Products, J. Clin. Psychiatry CNS Capsules, Volume 2, Issue 4, November 15, 2000 61: (2000)

107. Meyer, MC, Straughn, AB, Mhatre, RM, Hussain, A, Shah,VP, Bottom, CB, Cole, ET, Lasko, LL, Mallinowshi, and Williams, RL. The Effect of Gelatin Cross-Linking on the Bioequivalence of Hard and Soft Gelatin Acetaminophen Capsules, Pharm.Res. 17:962-966 (2000)

108. Veng-Pedersen P, Gobburu JV, Meyer MC and Straughn AB. Carbamazepine Level-A In Vivo-In-Vitro Correlation (IVIVC): A Scaled Convolution Based Predictive Approach. Biopharm.Drug Dispos. 21:1-6 (2000).

109. Meyer, MC, Straughn, AB, Mhatre, RM, Shah, VP, Chen, ML, Williams, RL and Lesko, LJ. Variability in the Bioavailability of Phenytoin Capsules in Males and Females. Pharm. Res. 18:394-397 (2001).

110. Meyer, MC. United States Food and Drug Administration Requirements for Approval of Generic Drug Products. J. Clin. Psychiatry. 62: 4-9, Supplement 5 (2001)

111. Meyer, MC, Yacobi, I and Shah, VP. Similarities and Differences Among Various Regulatory Guidances for Bioequivalence Studies. Amidon, GL, Lesko, LJ, Midha, K and Shah, VP eds. AAPS Press, Alexandria, VA. 2001. In Review.

112. Dalton JT, Yates CR,Yin D, Straughn A, Marcus SL, Golub AL, Meyer MC Clinical pharmacokinetics of 5-aminolevulinic acid in healthy volunteers and patients at high risk for recurrent bladder cancer.. J Pharmacol Exp Ther. 301:507-1 (2002).

Research Grants Awards:

Principal Investigator Unrestricted Research Grant	Mead Johnson Laboratories	Sept. 1969- Dec. 1974	$ 8,000
Investigator "Developmental and Quality Control Studies"	National Cancer Institute, Natl. Institutes of Hlth. Contract NIH 70-2084	June 1970-	$ 164,000
Director	Mead Johnson	Sept. 1970-	$ 1,000

Undergraduate Research Award	Laboratories	Aug. 1971	
Principal Investigator "Study of the Bioavailability of Drugs Administered as Rectal Suppositories"	Marion Laboratories Research Grant	Nov. 1971-	$ 4,300
Principal Investigator "Drug Quality Assurance Program"	State of Tennessee Department of Public Health	July 1972- June 1989	$2,559,295
Principal Investigator "Drug Analysis Program"	Marion Laboratories Research Grant	Apr. 1973- Dec. 1973	$ 8,500
Principal Investigator "Bioavailability Evaluation Program"	U.S. Food and Drug Administration	June 1974-	$ 156,150
Principal Investigator Analytical and Stability Studies of Phenylephrine Pro-drug	Vick Chemical Co.	Jan. 1976-	$ 2,500
Principal Investigator "Evaluation of Beckman, Inc. Sartorius Solubility Absorption Simulator"	Sartorius Filters	June 1976-	$ 13,000
Principal Investigator "Bioavailability Studies"	Bell Pharmacal	Jan. 1977- June 1977	$ 8,300
Principal Investigator "Bioavailability Studies"	Cooper Laboratories	Mar. 1977- Dec. 1977	$ 17,340
Principal Investigator "Bioavailability Studies"	Cord Laboratories	June 1977- Dec. 1977	$ 16,212
Principal Investigator "Bioavailability Evaluation Program"	U.S. Food and Drug Administration	Sep. 1977- Jan. 1981	$ 309,895
Program Director Clinical Pharmacokinetics of Cancer Drugs	National Cancer Institute	Sep. 1978- Aug. 1981	$ 83,400
Principal Investigator "Bioavailability Studies"	Cooper Laboratories	Jan. 1979	$ 17,500
Principal Investigator "Bioavailability Studies"	Marion Laboratories	Apr. 1979	$ 19,200
Principal Investigator "Bioavailability Studies"	Cooper Laboratories	July 1979	$ 11,778

Principal Investigator "Bioavailability Studies"	Pharmadyne Corp.	Aug. 1979	$	14,800
Principal Investigator "Bioavailability Studies"	Glaxo Laboratories	Dec. 1979	$	17,000
Principal Investigator "Bioavailability Studies"	Berlex Laboratories	Apr. 1980	$	15,600
Principal Investigator "Bioavailability Studies"	Berlex Laboratories	May 1980	$	13,027
Principal Investigator "Bioavailability Studies"	Glaxo Laboratories	June 1980	$	15,500
Principal Investigator "Bioavailability Studies"	Glaxo Laboratories	July 1980	$	9,000
Principal Investigator "Bioavailability Studies"	Berlex Laboratories	Dec. 1980	$	9,000
Principal Investigator "Bioavailability Studies"	Glaxo Laboratories	Feb. 1981	$	38,300
Principal Investigator Cephalosporin Pharma-cokinetics"	Pfizer Laboratories	Apr. 1981	$	24,719
Principal Investigator "Bioavailability Studies"	Cord Laboratories	May 1981	$	49,000
Principal Investigator "Biomedical Research Support Group"	NIH	Nov. 1981	$	14,686
Principal Investigator "Bioavailability Studies"	PharmaKinetics Labs	Oct. 1981	$	9,040
Principal Investigator "Bioavailability Studies"	Cord Labs	Nov. 1981	$	26,000
Principal Investigator "Bioavailability Studies"	Key Pharmaceuticals	Dec. 1981	$	6,080
Principal Investigator "Ceftazidime Pharmacoki-netics in Renal Patients"	Glaxo Laboratories	Dec. 1981	$	34,300
Principal Investigator "Continuous Ambulatory Peritoneal Dialysis"	Glaxo Laboratories	July 1982	$	15,000
Principal Investigator "Bioavailability Studies"	Key Pharmaceuticals	Aug. 1982	$	10,000

Principal Investigator "Bioavailability Studies"	Pennwalt Corp.	Aug. 1982	$	27,000
Principal Investigator "Naltrexone Pharmaco-kinetics"	Dupont Corp.	Nov. 1982	$	39,240
Principal Investigator "Bioavailability Studies"	Key Pharmaceuticals	Nov. 1982	$	14,000
Principal Investigator "Bioavailability Studies"	Key Pharmaceuticals	Dec. 1982	$	18,000
Principal Investigator "Bioavailability Studies"	Key Pharmaceuticals	Feb. 1983	$	18,000
Principal Investigator "Bioavailability Studies"	Key Pharmaceuticals	Mar. 1983	$	12,000
Principal Investigator "Bioavailability Studies"	Cord Laboratories	May 1983	$	20,000
Principal Investigator "Bioavailability Studies"	Duramed Pharmaceut.	July 1983	$	20,000
Principal Investigator "Bioavailability Studies"	Key Pharmaceuticals	July 1983	$	6,750
Principal Investigator "Bioavailability Studies"	Key Pharmaceuticals	Aug. 1983	$	27,720
Principal Investigator "Bioavailability Studies"	Biodecision Labs	Aug. 1983	$	6,000
Principal Investigator "Bioavailability Studies"	Danbury Pharmacal	Sep. 1983	$	31,500
Principal Investigator "Bioavailability Studies"	International Drug Registration	Nov. 1983	$	65,869
Principal Investigator "Bioavailability Studies"	Glaxo Laboratories	Dec. 1983	$	47,520
Principal Investigator "Bioavailability Studies"	Purdue Frederick Co.	Dec. 1983	$	28,000
Principal Investigator "Bioavailability Studies"	Key Pharmaceuticals	Jan. 1984	$	1,000
Co-Principal Investigator "Bioavailability Studies"	Key Pharmaceuticals	Jan.1984	$	51,000
Co-Principal Investigator "Bioavailability Studies"	Pennwalt Corporation	Jan.1984	$	36,500
Principal Investigator "Bioavailability Studies"	Purdue Frederick Co.	Feb. 1984	$	36,457

Principal Investigator "Bioavailability Studies"	Pfizer Laboratories	Feb. 1984		$ 43,000
Principal Investigator "Bioavailability Studies"	Key Pharmaceuticals	Feb. 1984		$ 22,690
Principal Investigator "Bioavailability Studies"	International Drug Registration	Feb. 1984		$ 31,088
Principal Investigator "Bioavailability Studies"	Key Pharmaceuticals	April 1984		$ 29,330
Principal Investigator "Bioavailability Studies"	Danbury Pharmacal	May 1984		$ 23,599
Principal Investigator "Bioavailability Studies"	U.S Food and Drug Administration	June 1984-June 1987		$ 558,000
Principal Investigator "Bioavailability Studies"	Cord Laboratories	July 1984	$ 89,000	
Principal Investigator "Bioavailability Studies"	Sidmak Pharm.	July 1984	$ 24,767	
Principal Investigator "Bioavailability Studies"	Key Pharmaceuticals	Aug. 1984	$ 21,266	
Principal Investigator "Bioavailability Studies"	Duramed Pharm.	Aug.1984	$ 16,200	
Co-Principal Investigator "Bioavailability Studies"	Key Pharmaceuticals	Sept.1984	$ 22,000	
Principal Investigator "Bioavailability Studies"	International Drug Registration	Nov. 1984	$ 25,000	
Co-Principal Investigator "Bioavailability Studies"	Beecham Labs	Mar. 1985	$ 45,654	
Co-Principal Investigator "Bioavailability Studies"	Key Pharmaceuticals	Mar.1985	$ 11,000	
Co-Principal Investigator "Bioavailability Studies"	Key Pharmaceuticals	Apr. 1985	$ 42,306	
Principal Investigator "Bioavailability Studies"	Key Pharmaceuticals	Aug. 1985	$ 20,900	
Co-Principal Investigator "Bioavailability Studies"	Key Pharmaceuticals	Sept. 1985	$ 25,600	
Principal Investigator "Bioavailability Studies"	International Drug Registration	Sept. 1985	$ 67,600	
Principal Investigator "Bioavailability Studies"	Cord Laboratories	Oct. 1985	$ 73,000	

Co-Principal Investigator "Bioavailability Studies"	Glaxo Laboratories	Dec. 1985	$	19,700
Principal Investigator "Bioavailability Studies"	Colmed Laboratories	Jan. 1986	$	32,000
Co-Principal Investigator "Bioavailability Studies"	M.D. Pharmaceuticals	Apr. 1986	$	102,583
Co-Principal Investigator "Bioavailability Studies"	Cord Laboratories	Apr. 1986	$	86,540
Co-Principal Investigator "Bioavailability Studies"	Glaxo Laboratories	May 1986	$	18,716
Principal Investigator "Bioavailability Studies"	Sidmak Laboratories	May 1986	$	67,300
Principal Investigator "Bioavailability Studies"	Ganes Chemical Co., New York, NY	Jan. 1987	$	23,500
Co-Principal Investigator "Bioavailability Studies"	Key Pharmaceuticals	Jan. 1987	$	20,068
Principal Investigator "Bioavailability Studies"	Sidmak Laboratories	Jan. 1987	$	56,314
Principal Investigator "Bioavailability Studies"	Vitarine Pharm.	Mar. 1987	$	32,000
Principal Investigator "Bioavailability Studies"	Beecham Laboratories	Apr. 1987	$	60,690
Principal Investigator "Bioavailability Studies"	Sidmak Laboratories	May 1987	$	25,200
Principal Investigator "Bioavailability Studies"	Sidmak Laboratories	June 1987	$	33,800
Principal Investigator "Assay Development"	Sidmak Laboratories	June 1987	$	10,000
Principal Investigator "Bioavailability Studies Evaluations"	Siegfried AG	Aug. 1987	$	57,600
Principal Investigator "Bioavailability Evaluations"	Sidmak Laboratories	Oct. 1987	$	32,000
Principal Investigator "Bioavailability Evaluations"	Sidmak Laboratories	Oct. 1987	$	64,500
Co-Principal Investigator "Bioavailability Studies"	Schering	Nov. 1987	$	43,800
Co-Principal Investigator	Schering	Feb. 1988	$	63,029

"Bioavailability Studies"				
Co-Principal Investigator "Bioavailability Studies"	Glaxo	Jan. 1988	$	28,746
Principal Investigator "Bioavailability Evaluations"	Sidmak Laboratories	April 1988	$	44,200
Principal Investigator "Bioavailability Evaluations"	Sidmak Laboratories	Oct. 1988	$	118,000
Principal Investigator "Bioavailability Evaluations"	Vitarine	Mar. 1989	$	72,800
Principal Investigator Unrestricted	Ciba-Geigy	Aug. 1988	$	4,000
Principal Investigator "Bioavailability Evaluations"	Sidmak Laboratories	Feb. 1989	$	34,500
Principal Investigator "Bioavailability Evaluations"	Food and Drug Admin.	Sept. 1987-Sept. 1990	$	487,725
Principal Investigator "Drug Quality Assurance Program"	State of Tennessee Department of Public Health	July 1989-June 1990	$	142,015
Co-Principal Investigator "Theophylline Kinetics"	Schering Corporation	Sept. 1988	$	17,820
Principal Investigator "New Assay Methods"	Sidmak Laboratories	Oct. 1988	$	30,000
Co-Principal Investigator "Theophylline Bioavail-ability"	Schering Corporation	Nov. 1988	$	23,640
Principal Investigator "Griseofulvin Bioavail-ability"	Sidmak Laboratories	Nov. 1988	$	88,000
Co-Principal Investigator "Theophylline Bioavail-ability"	Schering Corporation	Dec. 1988	$	27,930
Principal Investigator "Diazepam Studies"	Vitarine Laboratories	Mar. 1989	$	34,000
Co-Investigator "Pediatric Theophylline"	Schering Corporation	Apr. 1989	$	8,420
Co-Principal Investigator	Kos Pharmaceuticals	Apr. 1989	$	3,280

"Aspirin Effect on Niacin Induced Flushing"				
Principal Investigator "Drug Quality Assurance Program"	State of Tennessee Department of Public Health	July 1989-June 1990	$	106,897
Co-Principal Investigator "Antacids and Theophylline"	Schering Corporation	Nov. 1989	$	38,960
Co-Principal Investigator "Ped S-R Theo Kinetics"	Schering Corporation	Dec. 1989	$	14,850
Co-Principal Investigator "Theophylline Kinetics"	Schering Corporation	Dec. 1989	$	15,120
Co-Principal Investigator "Steady-State Theophylline"	Schering Corporation	Dec. 1989	$	16,200
Co-Investigator "New Dosage Forms"	Kos Pharmaceuticals	Apr. 1990	$	13,220
Principal Investigator "Drug Quality Assurance Program"	State of Tennessee Department of Public Health	July 1991-June 1992	$	106,695
Co-Principal Investigator "Food Effect on Sprinkle"	Schering Corporation	July 1990	$	53,840
Co-Principal Investigator "Sprinkle/Intact Dosages"	Schering Corporation	Aug. 1990	$	18,389
Co-Principal Investigator "Food Effect on Absorption"	Kos Pharmaceuticals	Sept. 1990	$	31,384
Co-Principal Investigator "Pilot Effect of Food"	Kos Pharmaceuticals	Dec.1990	$	14,400
Co-Investigator "Flux Studies"	Venture Pharma.	Dec. 1990	$	6,000
Co-Principal Investigator "Single Dose Theophylline"	Schering Corporation	Dec. 1990	$	58,638
Co-Principal Investigator "Steady-State Once-A-Day Theophylline Sprinkle"	Schering Corporation	Dec. 1990	$	20,375
Principal Investigator "Bioavailability Studies"	Vitarine	Jan. 1991	$	33,501
Co-Principal Investigator "Uni-Dur Absorption"	Schering Corp.	Jan. 1991	$	47,082
Principal Investigator "Clonazepam Absorption"	Hoffman LaRoche	Feb. 1991	$	69,000

Principal Investigator "Bioequivalence Studies of Selected Drug Procedures"	U.S. FDA	July 1,1991- June 30, 1994	$	584,575
Principal Investigator "Bioequivalence Studies"	MD Pharmaceuticals	July 1991	$	79,488
Co-Investigator "Bioavailability Study"	Whitby Research	August 1992	$	38,110
Principal Investigator EC Tablets & Gastric Emptying	Ciba-Geigy	January 1993	$	5 7,250
Co-Investigator Food Effect Study	Kos Pharmaceuticals	March 1993	$	44,024
Principal Investigator Bioequivalence Studies	Eon Labs	May 1993	$	50,083
Principal Investigator PK/PD Studies	Schering Corp.	May 1993	$	82,122
Principal Investigator Assay Development	Dusa, Inc.	May 1993	$	5,298
Principal Investigator Bioequivalence Studies	Eon Labs	July 1993	$	52,240
Principal Investigator Piroxicam Studies	Univ. of Maryland	July 1993	$	115,959
Principal Investigator Assay Development	Eon Laboratories	Oct. 1993	$	8,000
Principal Investigator Assay Development	Eon Laboratories	Oct. 1993	$	52,420
Principal Investigator Assay Development	Eon Laboratories	Dec. 1993	$	71,474
Principal Investigator Generic Drug Studies	U.S. FDA	July 1994	$	110,000
Principal Investigator Bioequivalence Study	Univ. of Maryland	Sept. 1994	$	19,875
Principal Investigator "Generic Drug Studies"	U.S. Food and Drug Administration	Jan.1995- March 1998	$	689,061
Co-Principal Investigator Bioequivalence Study	Timerx Technologies	Sept. 1994	$	27,970
Co-Principal Investigator Bioequivalence Study	Timerx Technologies	Nov. 1994	$	29,193
Co-Principal Investigator "Transdermal Absorption	Sano Corporation	Jan. 1995	$	29,156

of Drugs in Humans"

Co-Principal Investigator Bioequivalence Study	Timerx Technologies	March 1995	$	21,956
Co-Principal Investigator "Effect of Food"	Timerx Technologies	April 1995	$	30,736
Principal Investigator Bioequivalence Study	Timerx Technologies	April 1995	$	30,736
Principal Investigator Bioequivalence Study	Daniels Pharmac.	July 1995	$	47,693
Co-Principal Investigator Bioequivalence Study	Timerx Technologies	Aug. 1995	$	37,428
Co-Principal Investigator Bioequivalence Study	Timerx Technologies	Oct. 1995	$	33,095
Co-Principal Investigator Bioequivalence Study	Timerx Technologies	Oct. 1995	$	37,428
Co-Principal Investigator Bioequivalence Study	Timerx Technologies	March 1995	$	21,956
Co-Principal Investigator Bioequivalence Study	Timerx Technologies	Jan. 1996	$	57,422
Co-Principal Investigator Bioequivalence Study	Timerx Technologies	Jan. 1996	$	33,140
Principal Investigator Bioequivalence Study	Guidelines, Inc.	Jan. 1996	$	45,283
Co-Principal Investigator Bioequivalence Study	Sano Corp.	Jan. 1996	$	41,232
Principal Investigator Pilot Study	Psoralen, Inc.	Dec. 1996	$	13,330
Principal Investigator Bioequivalence Study	Psoralen, Inc.	March 1997	$	47,611

Investigators: A.B. Straughn (PI) and M.C. Meyer (Co-PI)
Source: Timerx Technologies, Inc.
Project Title: Bioavailability of Sustained-Release Dosage Forms (Supplement 19)
Funding Period: July 1997 - October 1997
Total Direct: $32,948.40
Report Year Direct: $32,948.40

Investigators: A.B. Straughn (PI) and M.C. Meyer (Co-PI)
Source: Timerx Technologies, Inc.
Project Title: Bioavailability of Sustained-Release Dosage Forms (Supplement 20)
Funding Period: October 1997 - December 1997
Total Direct: $32,888.40
Report Year Direct: $32,888.40

Investigators: A.B. Straughn (PI) and M.C. Meyer (Co-PI)
Source: Timerx Technologies, Inc.
Project Title: Bioavailability of Sustained-Release Dosage Forms (Supplement 21)
Funding Period: October 1997 - December 1997
Total Direct: $32,948.40
Report Year Direct: $32,948.40

Investigators: A.B. Straughn (PI) and M.C. Meyer (Co-PI)
Source: Penwest Pharmaceuticals Company
Project Title: Bioavailability of Sustained-Release Dosage Forms (Supplement 22)
Funding Period: February 1998- June 1998
Total Direct: $39,598.80
Report Year Direct: $39,598.80

Investigators: A.B. Straughn (PI) and M.C. Meyer (Co-PI)
Source: Penwest Pharmaceuticals Company
Project Title: Bioavailability of Sustained-Release Dosage Forms (Supplement 23)
Funding Period: February 1998 - June 1998
Total Direct: $40,102.80
Report Year Direct: $40,102.80

Investigators: A.B. Straughn (PI) and M.C. Meyer (Co-PI)
Source: Penwest Pharmaceuticals Company
Project Title: Bioavailability of Sustained-Release Dosage Forms (Supplement 24)
Funding Period: April 1998 - December 1998
Total Direct: $32,888.40
Report Year Direct: $32,888.40

Investigators: A.B. Straughn (PI) and M.C. Meyer (Co-PI)
Source: Penwest Pharmaceuticals Company
Project Title: Bioavailability of Sustained-Release Dosage Forms (Supplement 25)
Funding Period: April 1998 - December 1998
Total Direct: $32,948.40
Report Year Direct: $32,948.40

Investigators: M.C. Meyer (PI) and A.B. Straughn (Co-PI)
Source: Cogent Pharmaceuticals
Project Title: Bioavailability of a Transdermal Delivery System
Funding Period: July 1998 - June 1999
Total $62,205
Report Year: $62,205

Investigators: M.C. Meyer (PI) and A.B. Straughn (Co-PI)
Source: Cogent Pharmaceuticals
Project Title: Bioavailability of a Transdermal Delivery System in Elderly
Funding Period: July 1998 - June 1999
Total Direct: $99,570
Report Year: $99,570

Investigators: M.C. Meyer (PI) and A.B. Straughn (Co-PI)
Source: Selectus Pharmaceuticals
Project Title: Bioavailability of a Buccal Delivery System
Funding Period: July 1998 - June 1999
Total Direct: $59,850

Report Year: $59,850

Investigators: M.C. Meyer (PI) and A.B. Straughn (Co-PI)
Source: Levotech Pharmaceuticals
Project Title: Bioavailability of a Transdermal Delivery System
Funding Period: July 1998 - June 1999
Total Direct: $21,546
Report Year: $21,546

Investigators: M.C. Meyer (PI) and A.B. Straughn (Co-PI)
Source: Banner Pharmacaps, Inc.
Project Title: Bioavailability of an OTC Analgesic
Funding Period: July 1998 - June 1999
Total Direct: $89,493
Report Year: $89,493

Investigators: A.B. Straughn (PI) and M.C. Meyer (Co-PI)
Source: Timerx Technologies, Inc.
Project Title: Bioavailability of Sustained-Release Dosage Forms (Suppl. 26)
Funding Period: July 1998 - June 1999
Total Direct: $38,438
Report Year Direct: $38,438

Investigators: A.B. Straughn (PI) and M.C. Meyer (Co-PI)
Source: Timerx Technologies, Inc.
Project Title: Bioavailability of Sustained-Release Dosage Forms (Suppl. 27)
Funding Period: July 1998 - June 1999
Total Direct: $56,487
Report Year Direct: $56,487

Investigators: A.B. Straughn (PI) and M.C. Meyer (Co-PI)
Source: Timerx Technologies, Inc.
Project Title: Bioavailability of Sustained-Release Dosage Forms (Suppl. 28)
Funding Period: July 1998 - June 1999
Total Direct: $57,167
Report Year Direct: $57,167

Investigators: A.B. Straughn (PI) and M.C. Meyer (Co-PI)
Source: Penwest Pharmaceuticals Company
Project Title: Bioavailability of Sustained-Release Dosage Forms (Suppl. 29)
Funding Period: February 1998- June 1998
Total Direct: $39,517
Report Year Direct: $39,517

Investigators: A.B. Straughn (PI) and M.C. Meyer (Co-PI)
Source: Timerx Technologies, Inc.
Project Title: Bioavailability of Sustained-Release Dosage Forms (Suppl. 30)
Funding Period: July 1998 - June 1999
Total Direct: $39,972
Report Year Direct: $39,972

Investigators: A.B. Straughn (PI) and M.C. Meyer (Co-PI)
Source: Levotech
Project Title: Bioavailability of a Transdermal Delivery System-II & III
Funding Period: 1999-2000
Total Direct: $66,000
Report Year Direct: $66,000

Investigators:M.C. Meyer (PI) and A.B. Straughn (Co-PI)
Source: Food and Drug Administration
Project Title: Bioavailability of Selected Drug Products (Supplemental Award)
Funding Period:March 2001-February 2002
Total Direct: $70,082
Report Year Direct: $70,082

Investigators: A.B. Straughn (PI) and M.C. Meyer (Co-PI)
Source: Focus Pharmaceuticals
Project Title: Bioavailability of a Chiral Product
Funding Period: Oct. 2000-May 2001
Total Direct: $54,310
Report Year Direct: $54,310

Investigators: A.B. Straughn (PI) and M.C. Meyer (Co-PI)
Source: Timerx Technologies, Inc.
Project Title: Bioavailability of Sustained-Release Dosage Forms (Suppl. 31)
Funding Period: Oct. 2000-April 2001
Total Direct: $76,234
Report Year Direct: $76,234

TOTAL = $11,562,888